Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Boston Scientific (BSX)

Boston Scientific to acquire Penumbra under merger agreement signed January 14, 2026

Neutral Impact 5 of 5 m&a Written later

On January 14, 2026, Boston Scientific entered a Merger Agreement under which Penumbra will merge into a Boston Scientific subsidiary and become a wholly owned subsidiary. Penumbra stockholders can elect $374.00 in cash or 3.8721 Boston Scientific shares per share, subject to proration that sets 73.26% of shares for cash and 26.74% for stock. Completion depends on Penumbra stockholder approval, antitrust and other regulatory clearances, and other conditions, and the filing excerpt ends before the full termination terms are described.

Key points

  • Cash election: $374.00 per Penumbra share; stock election: 3.8721 Boston Scientific shares per Penumbra share
  • Proration: 73.26% of Penumbra shares receive cash and 26.74% receive Boston Scientific stock
  • Penumbra equity awards: $274.00 in cash plus 1.0353 Boston Scientific shares, measured against a 10-day average trading price
  • Penumbra would pay Boston Scientific a $525,000,000 termination fee in specified circumstances

The filing

CompanyBoston Scientific (BSX)
Form8-K, current report
Filed with the SECJan 15, 2026, 5:05 PM ET
Accession number0000947871-26-000037

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.